Trade Summary

Yesterday, Congleton Jon, serving as Chief Executive Officer at Mineralys Therapeutics, Inc. (MLYS), sold 75,000 shares at $26.14 per share, for a total transaction value of $1,960,601.40. Following this transaction, Congleton Jon now holds 614,321 shares of MLYS.

This sale represents a 10.88% decrease in Congleton Jon's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Tuesday, June 30, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, June 30, 2026 at 6:41 PM ET, meaning the disclosure happened on the same day as the trade.

Mineralys Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.